ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4 | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

Pancreas

Original research

ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4

Online download statistics by month:

Online download statistics by month: March 2021 to October 2023

	Abstract	Full	Pdf
Mar 2021	2072	154	128
Apr 2021	721	33	18
May 2021	172	44	19
Jun 2021	26	26	17
Jul 2021	35	31	13
Aug 2021	31	26	14
Sep 2021	27	23	17
Oct 2021	449	37	16
Nov 2021	545	28	24
Dec 2021	505	39	13
Jan 2022	1198	69	45
Feb 2022	1227	77	48
Mar 2022	1121	85	44
Apr 2022	712	77	36
May 2022	684	43	20
Jun 2022	522	51	18
Jul 2022	404	39	15
Aug 2022	563	52	22
Sep 2022	470	25	6
Oct 2022	610	50	14
Nov 2022	536	52	31
Dec 2022	347	26	14
Jan 2023	326	33	12
Feb 2023	325	23	16
Mar 2023	217	27	10
Apr 2023	164	26	15
May 2023	129	7	2
Jun 2023	182	12	1
Jul 2023	199	23	6
Aug 2023	174	22	1
Sep 2023	228	32	2
Oct 2023	421	19	6
Total	15342	1311	663